Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm
NCT ID: NCT06545344
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2025-09-01
2026-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
NCT02307539
Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer
NCT01760694
The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.
NCT01996540
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326
Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient
NCT06090825
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ARM I: Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.
ARM II: Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.
After completion of study intervention, patients are followed up 7 days after the tumor board visit and 90 days after initiation of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (Usual care)
Patients receive usual care and undergo evaluation by a tumor board within 14 days of baseline.
Best Practice
Receive usual care
Survey Administration
Ancillary studies
Tumor Board Review
Undergo evaluation by tumor board
Arm II (Palliative care visit)
Patients attend a palliative care visit over 60 minutes to discuss their illness, quality of life, fears and concerns and communication preferences within 7 days of baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.
Palliative Care Consultation
Attend a palliative care visit
Survey Administration
Ancillary studies
Tumor Board Review
Undergo evaluation by tumor board
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Best Practice
Receive usual care
Palliative Care Consultation
Attend a palliative care visit
Survey Administration
Ancillary studies
Tumor Board Review
Undergo evaluation by tumor board
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pancreatic neoplasm pathology
* Ability to read, write, and speak in English
* Has decisional capacity
* Expected to be seen and discussed at PCSC and seeing a surgeon as part of their tumor board evaluation
Exclusion Criteria
* Currently incarcerated
* Currently is or previously has received palliative care, or are unwilling to forego palliative care for the first 90 days post randomization
* Evidence of any behavior, condition, or circumstance (including, but not limited to: blindness, deafness, serious behavior or mental health conditions, discontinuing curative treatment, lack of access to technology, etc) that would interfere with their ability to complete study procedures as noted within the chart
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elizabeth Loggers
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-05662
Identifier Type: REGISTRY
Identifier Source: secondary_id
20350
Identifier Type: OTHER
Identifier Source: secondary_id
RG1124214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.